WVE - Wave Life Sciences Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Wave Life Sciences Ltd.

Marina One East Tower
No. 12-00, 7 Straits View
Singapore 018936
65 6236 3388

Full Time Employees250

Key Executives

NameTitlePayExercisedYear Born
Dr. Paul B. BolnoPres, CEO & Director854.64k2.13M1974
Mr. Keith C. RegnanteExec. Officer501.86k1.01M1970
Dr. Christopher Francis Ph.D.Sr. VP of Corp. Devel. & Head of Emerging Areas493.13k4.75M1978
Dr. Chandra VargeeseSr. VP of Drug Discovery573.77k327.3k1961
Dr. Michael A. PanzaraChief Medical Officer615.35k530.81k1967
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics; and research, development, and commercial collaboration and multi-program option agreement with Wave Life Sciences Ltd. to develop antisense oligonucleotides. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

Corporate Governance

Wave Life Sciences Ltd.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.